0001434647-26-000031
SEC filingZevra Therapeutics delivered strong Q1 2026 results with revenue up 77.5% to $36.2M and operating income swinging to $52.1M profit from a $5.4M loss, fueled by robust product sales and one-time gains that drove positive cash flow of $6.1M.
Zevra Therapeutics reported transformative Q1 2026 financials, with revenue climbing 77.5% year-over-year to $36.2 million from $20.4 million. This growth underscores the company's progress in commercializing approved products like MIPLYFFA and securing product reimbursements under the global Expanded Access Program (EAP), as anticipated in management commentary. The revenue expansion directly contributed to operating income flipping to a robust $52.1 million profit—up 1072.5% from a $5.4 million loss—yielding an exceptional 144.0% operating margin. Investors should note this margin reflects the interplay of scaled revenue against fixed cost structures, amplified by non-recurring elements that boosted overall profitability.
Net income followed suit at $37.9 million (1322.7% YoY improvement from -$3.1 million), delivering diluted EPS of $0.60 versus -$0.06. This swing demonstrates how revenue momentum and profitability gains outweighed expense pressures, positioning Zevra for sustained earnings potential as product sales mature. Cash flow dynamics also improved markedly: net cash provided by operating activities reached $6.1 million, reversing an $8.2 million use in Q1 2025. After minimal capital expenditures of $35 thousand, free cash flow stood at $6.1 million. This positive generation signals better working capital management and operational efficiency, even as the company invests in its pipeline.
Post-period, Relief sold royalty rights to Soleus Capital Management on April 10, 2025, potentially streamlining future economics. Management notes that inventory capitalization prior to approval hinges on probable commercialization, with otherwise expensed costs routed to R&D—contextualizing balance sheet decisions. Looking forward, Zevra expects revenue from approved product sales, EAP reimbursements, and related arrangements, though significant expenses may lead to fluctuating cash flows quarter-to-quarter. This Q1 performance validates commercial traction and pipeline commitment, enhancing liquidity and investor confidence amid biotech volatility.